

---

---

## CONTENT

<b>1-</b>	1
<b>Introduction.....</b>	
<b>2- Review of</b>	4
<b>literature.....</b>	
2.1. Foot and Mouth	4
Disease.....	
2.1.1. History in the	4
world.....	
2.1.2. History in	6
Egypt.....	
2.1.3. Classification of foot and mouth disease	7
virus.....	
2.1.4. Morphology of FMD	8
virus.....	
2.1.5. Structure of FMD	9
virus.....	
2.1.6. Physico-Chemical properties of FMD	11
Virus.....	
2.1.7. Antigenic components of FMD	12
virus.....	
2.1.7.1. Structural	12
antigens.....	
2.1.7.2. Non- structural proteins	12
(NSP).....	
2.1.8. Typing and subtyping of FMD	13
virus.....	
2.1.9. Propagation of	15

---

---

FMDv.....	
2.1.10 Host susceptibility.....	16
2.1.11. Transmission of FMDv.....	16
2.1.12. Pathogenesis of FMDv.....	17
2.1.13. Foot and Mouth Disease Vaccines.....	18
2.1.13.1. Inactivated FMD vaccine.....	19
2.1.13.1.1. Oil inactivated FMD Vaccine.....	21
2.1.13.2. Genetically engineered FMD vaccines.....	23
2.1.13.3. FMD combined vaccine containing other antigens.....	24
2.2. Bovine Ephemeral Fever virus (BEF).....	28
2.2.1. History in the world.....	28
2.2.2. History of BEF in Egypt.....	30
2.2.3. Classification of BEFv.....	31
2.2.4. Morphology of BEFv.....	32
2.2.5. Structure of BEFv.....	32
2.2.6. Physico-chemical	35

---

---

properties.....	
2.2.7. Antigenic characters of BEFv.....	36
2.2.8. Cultivation of BEFv.....	37
2.2.8.1. Propagation of BEFv in laboratory animals.....	37
2.2.8.2. Propagation of BEFv in tissue culture.....	38
2.2.9. Host susceptibility.....	39
2.2.10. Virus transmission and mode of infection.....	40
2.2.10. Viral pathogenicity.....	41
2.2.11. BEF vaccines.....	42
2.2.11.1. Live attenuated BEF vaccines.....	42
2.2.11.2. Inactivated BEF vaccines.....	43
2.2.11.3. Genetically engineered BEF vaccine.....	46
<b>3- Materials and Methods.....</b>	<b>47</b>
<b>3.1. Materials.....</b>	<b>47</b>
3.1.1. Virus.....	47
3.1.2. Serum Samples.....	47

---

3.1.3. Tissue culture.....	48
3.1.4. Tissue culture media and Solutions.....	48
3.1.5. Reagent for virus concentration.....	50
3.1.6. Reagents for vaccine preparation.....	50
3.1.7. Materials used for SNT	51
3.1.8. Material used for ELISA.....	52
3.1.9. Experimental Animals.....	55
<b>3.2. Methods.....</b>	<b>56</b>
3.2.1. Propagation of FMD and BEF viruses.....	56
3.2.2. Titration of FMD and BEF viruses.....	56
3.2.3. Virus purification.....	57
3.2.4. FMD Virus concentration.....	57
3.2.5. Preparation of inactivated vaccines.....	58
3.2.6. Evaluation of the prepared vaccines.....	60
3.2.7. Experimental design.....	61
3.2.7.1. Vaccination of animal groups.....	61
3.2.7.2. Collection of serum samples.....	62
3.2.7.3. Evaluation of the prepared vaccines (SNT, ELISA).....	63

---

3.2.7.4. Challenge test.....	67
<b>4. Results.....</b>	<b>68</b>
<b>5. Discussion.....</b>	<b>133</b>
<b>6. Summary.....</b>	<b>144</b>
<b>7. References.....</b>	<b>146</b>

## LIST OF ABBRIVIATIONS

<b>A</b>	:	Angstrom
<b>Ab</b>	:	Antibodies
<b>AEI</b>	:	Acetyl ethelenimine
<b>AL(OH)<sub>3</sub></b>	:	Aluminum hydroxide gel
<b>BAL</b>	:	Bovine albumine
<b>BEF</b>	:	Bovine ephemeral fever
<b>BEI</b>	:	Binary- Ethylene-Imine
<b>BHK<sub>21</sub></b>	:	Baby Hamster Kidney cell line 21
<b>CFA</b>	:	Complete Freund adjuvant
<b>CFT</b>	:	Complement Fixation Test
<b>CPE</b>	:	Cytopathic Effect
<b>DDW</b>	:	Double Distilled Water
<b>DOE</b>	:	Double oil emulsion
<b>dpv</b>	:	Dayes post vaccination
<b>ELISA</b>	:	Enzyme Linked Immunosorbent Assay
<b>FA</b>	:	Formalin
<b>FMD</b>	:	Foot and Mouth Disease
<b>FMDV</b>	:	Foot and Mouth Disease Virus
<b>GSLS</b>	:	ginseng stem and leaf saponins
<b>hr</b>	:	hours
<b>HS</b>	:	Hemolytic system
<b>IFA</b>	:	Incomplete Freund adjuvant
<b>IBR</b>	:	Institute of biological Remo
<b>I/P</b>	:	Intraperitoneal
<b>ISA</b>	:	Incomplete Seppic adjuvant
<b>I<sub>μ</sub></b>	:	International unite
<b>Kb</b>	:	Kilo base
<b>KDa</b>	:	Kilo dalton
<b>LD<sub>50</sub></b>	:	Lethal dose fifty
<b>MEM</b>	:	Minimum essential medium
<b>MHD</b>	:	Minimum Haemolytic Dose
<b>M</b>	:	Mole
<b>MLD50</b>	:	Minimum lethal dose fifty

---

## **6. SUMMARY**

Regular Prophylactic vaccination of cattle and buffalo against Foot and Mouth disease virus and Bovine ephemeral fever virus has become an important input to maintain animal productivity and to reduce economic losses in Egypt.

Due to the economic losses caused by FMD and BEF viruses and advantages claimed to be offered by combined vaccines as it have many benefits for the manufacturer , administrator and for the animal health ,the present study was undertaken to evaluate the ability of prepared combined inactivated oil FMD+BEF vaccine contains FMDV serotypes circulating in Egypt (O, A, SAT2) to promote sustained protective immune response in calves following single dose application compared with individual trivalent FMD, BEF vaccines.

Three experimental batches of trivalent FMD, BEF and combined FMD /BEF vaccines were prepared. Viruses were inactivated by binary ethyleneimine and adjuvanted with Montanide ISA 206 oil for preparation of (W/O/W) double oil emulsion vaccines, prepared vaccines were proven to be sterile and free from bacterial and fungal contamination or viable viral residuals.

Susceptible calves free from either FMD or BEF antibodies were divided into three groups. First group were vaccinated with FMD vaccine, second group were vaccinated with BEF vaccine and the third group were vaccinated with combined FMD/BEF vaccine. Serum samples were collected from the all groups weekly for one month then every two weeks and tested for determination of antibody titers against either FMD or BEF antigens using SNT and ELISA until reaching un-protective antibody level.

The results of potency testing of the three prepared vaccines in vaccinated calves showed the following results:

1- Protective antibody titer against FMD antigens elicited by either trivalent FMD or combined FMD/BEF started between 2<sup>nd</sup>, 3<sup>rd</sup> weeks post vaccination, antibody titers

---

gradually increased attained maximum level up to 6<sup>th</sup> and 8<sup>th</sup> week and maintained at level considered protective for a period ranged between 32 to 38 weeks.

2- Protective antibody titer against BEF antigen elicited by either BEF or combined FMD/BEF vaccine started at 2<sup>nd</sup> week post vaccination, attained maximum level at 8<sup>th</sup> week and lasted at level considered protective for a period ranged between 40 to 42 weeks post vaccination.

3-Potency testing of combined FMD/BEF vaccine against virulent FMDV was performed in calves vaccinated then challenged with three homologous serotypes FMD viruses (O, A, SAT2) 21 days post vaccination showed 100% protection which associated with seroconversion to the three serotypes.

4-statistical analysis of antibodies titers elicited by individual and combined vaccines showed no significant variation ( $p < 0.05$ ) in the serological response elicited by individual trivalent FMD, BEF vaccines and combined vaccine containing four antigens.

In conclusion cattle could be safely vaccinated with FMD/BEF combined vaccine without impairing the immune response against both antigens. Vaccination of large number of animals against important viral diseases like FMD and BEF in country like Egypt involve high manpower and labor cost. The approach of combined vaccine is a more intelligent approach, as it would save labor cost as well as the cost of adjuvant.